We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
South Korean biopharmaceutical firm GC Pharma has partnered with US-based Speragen to develop an enzyme replacement therapy for succinic semialdehyde dehydrogenase deficiency, reported The Korea Herald.